• J Trauma Acute Care Surg · Sep 2020

    Case Reports

    Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case series.

    • Christopher D Barrett, Achikam Oren-Grinberg, Edward Chao, Andrew H Moraco, Matthew J Martin, Srinivas H Reddy, Annette M Ilg, Rashi Jhunjhunwala, Marco Uribe, Hunter B Moore, Ernest E Moore, Elias N Baedorf-Kassis, Megan L Krajewski, Daniel S Talmor, Shahzad Shaefi, and Michael B Yaffe.
    • From the Division of Acute Care Surgery (C.D.B., R.J., M.B.Y.), Trauma and Surgical Critical Care, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; Departments of Biological Engineering and Biology (C.D.B., M.B.Y.), Koch Institute for Integrative Cancer Research, Center for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge; Department of Anesthesia (A.O.-G., A.M.I., M.L.K., D.S.T., S.S.), Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Division of Trauma and Surgical Critical Care (E.C., S.H.R., M.U.), Department of Surgery, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York; Division of Pulmonary and Critical Care (A.H.M.), Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts; Department of Surgery (M.J.M.), Scripps Mercy Hospital, San Diego, California; Department of Emergency Medicine (A.M.I.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Department of Surgery (H.B.M., E.E.M.), University of Colorado Denver, Aurora; Department of Surgery (E.E.M.), Ernest E Moore Shock Trauma Center at Denver Health, Denver, Colorado; Division of Pulmonary, Critical Care and Sleep Medicine (E.N.B.-K.), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
    • J Trauma Acute Care Surg. 2020 Sep 1; 89 (3): 453-457.

    AbstractThe coronavirus disease 2019 (COVID-19) pandemic has led to unprecedented stresses on modern medical systems, overwhelming the resource infrastructure in numerous countries while presenting a unique series of pathophysiologic clinical findings. Thrombotic coagulopathy is common in critically ill patients suffering from COVID-19, with associated high rates of respiratory failure requiring prolonged periods of mechanical ventilation. Here, we report a case series of five patients suffering from profound, medically refractory COVID-19-associated respiratory failure who were treated with fibrinolytic therapy using tissue plasminogen activator (tPA; alteplase). All five patients appeared to have an improved respiratory status following tPA administration: one patient had an initial marked improvement that partially regressed after several hours, one patient had transient improvements that were not sustained, and three patients had sustained clinical improvements following tPA administration. LEVEL OF EVIDENCE: Therapeutic, Level V.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.